Jiangsu Trautec Medical Technology Co., Ltd., a leading innovator in recombinant collagen production, officially debuted on the National Equities Exchange and Quotations (NEEQ) on November 11. Trading under the name Trautec Medical with the stock code 873474, this listing marks a significant milestone in China’s growing biopharmaceutical industry.

Based in Jintan district, Trautec Medical is celebrated for its advanced recombinant collagen fermentation technology. Recognized as a national “Little Giant” enterprise for its specialization and innovation, the company was also ranked as China’s top seller of raw materials in the recombinant collagen sector from 2022 to 2023, according to global consulting firm Frost & Sullivan.

Jintan has experienced remarkable economic development this year, with two companies achieving new listings, one entering the IPO counseling phase, one joining the NEEQ, and two completing shareholding reforms. These accomplishments highlight Jintan’s vibrant and dynamic business environment.

掃一掃在手機(jī)打開當(dāng)前頁